Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01706939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Aug 5, 2024, no change to tracked fieldsv17-v18
  2. Start date: Sep 2012 to Sep 1, 2012v16
  3. Results first posted: Sep 1, 2022
    • Primary endpoint revised
    • Enrollment target: 20 to 23
    • Secondary endpoints: 4 to 9
    v15
  4. Enrollment target: 24 to 20
    • Primary completion date changed from estimate of Dec 2021 to Apr 1, 2020
    • Study completion date: Dec 2021 to May 1, 2035
    • Secondary endpoints: details revised at 1 of 4 entries
    v14
  5. 3 versions Re-verified since Mar 22, 2019, no change to tracked fieldsv11-v13
Show 9 earlier versionsHide 9 earlier versions
  1. Interventions: Reduced Dose Radiation (Radiation), Standard Dose Radiation (Radiation) to Carboplatin (Drug), Reduced Dose Radiation (Radiation), Standard Dose Radiation (Radiation)v10
  2. Enrollment target: estimated 365 to confirmed 24v9 Show 4 more changesShow less
    • Primary completion date: Jun 2019 to Dec 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 2021 to Dec 2021
    • Site details revised
  3. Re-verified, no change to tracked fieldsv8
  4. Study title expanded, about 7 wordsv7
  5. Study sites: 2 to 1v6
  6. Study description shortened, about 6 wordsv5
  7. Eligibility criteria shortened, about 1 wordv4
  8. Study sites: 1 to 2v3
  9. Study description expanded, about 12 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
Trial Details
NCT Number NCT01706939
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: Biodesign Institute, Arizona State University
Conditions
(from sponsor)		 Squamous Cell Carcinomas
Related terms Carcinoma, Squamous Cell
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov